Scotland backs rare blood cancer drug Poteligeo rejected by NICEA north-south divide has emerged in UK medicines access after the Scottish Medicines Consortium (SMC) okayed Kyowa Kirin’s Share XScotland backs rare blood cancer drug Poteligeo rejected by NICEhttps://pharmaphorum.com/news/scotland-backs-rare-blood-cancer-drug-poteligeo-rejected-by-nice/
ASCO21: AZ seeks to supplant Imbruvica in CLL with new Calquence dataAstraZeneca has thrown down the gauntlet to AbbVie and Johnson & Johnson with new data for Calquence in Share XASCO21: AZ seeks to supplant Imbruvica in CLL with new Calquence datahttps://pharmaphorum.com/news/asco21-az-seeks-to-supplant-imbruvica-in-cll-with-new-calquence-data/
NICE backs AZ’s Calquence for new use in leukaemiaAstraZeneca’s BTK inhibitor Calquence has become the first targeted oral therapy to be backed by NICE for NHS Share XNICE backs AZ’s Calquence for new use in leukaemiahttps://pharmaphorum.com/news/nice-backs-azs-calquence-for-new-use-in-leukaemia/
AZ says Calquence is a safer drug than ImbruvicaAstraZeneca’s fast-growing BTK inhibitor Calquence is already challenging class leader Imbruvica from Johnson & Johnson/AbbVie in the treatment Share XAZ says Calquence is a safer drug than Imbruvicahttps://pharmaphorum.com/news/az-says-calquence-is-a-safer-drug-than-imbruvica/
AZ, Lilly join efforts to develop drugs for COVID-19AstraZeneca and Eli Lilly have joined the ranks of drugmakers around the world trying to repurpose existing drugs Share XAZ, Lilly join efforts to develop drugs for COVID-19https://pharmaphorum.com/news/az-lilly-join-efforts-to-develop-drugs-for-covid-19/
ASH19: AZ’s Calquence throws gauntlet down to ImbruvicaAstraZeneca’s resurgent cancer division could have another winner on its hands. Stellar data with newly-approved BTK inhibitor Calquence Share XASH19: AZ’s Calquence throws gauntlet down to Imbruvicahttps://pharmaphorum.com/news/ash19-azs-calquence-throws-gauntlet-down-to-imbruvica/
FDA nod for AZ’s Calquence sets up new Imbruvica showdownAbbVie and Johnson & Johnson are facing a challenge to their blockbuster chronic lymphocytic leukaemia drug Imbruvica from Share XFDA nod for AZ’s Calquence sets up new Imbruvica showdownhttps://pharmaphorum.com/news/fda-nod-for-azs-calquence-sets-up-new-imbruvica-showdown/
AZ/MSD’s PARP inhibitor shows promise as first-line ovarian cancer treatmentAstraZeneca and MSD’s Lynparza has scored its second Phase 3 win in the space of a week, this Share XAZ/MSD’s PARP inhibitor shows promise as first-line ovarian cancer treatmenthttps://pharmaphorum.com/news/az-msd-parp-inhibitor-ovarian-cancer/
AstraZeneca ends another Calquence trial earlyFor the second time in the space of a month AstraZeneca has stopped a trial of its chronic Share XAstraZeneca ends another Calquence trial earlyhttps://pharmaphorum.com/news/astrazeneca-ends-another-calquence-trial-early/
